Assertio (ASRT) Q4 2024 earnings summary

Executive summary

• 2024 was a year of stabilization, with a transition to Rolvedon as the lead asset and optimization of the cost structure following the Spectrum acquisition and Indocin's loss of exclusivity.

• Rolvedon sales exceeded $60 million, while Indocin sales declined due to generic competition.

• The company generated over $26 million in operating cash flow and strengthened its balance sheet.

• Leadership and board enhancements were made to support transformation and growth.

• Focus for 2025 includes driving revenue growth in Rolvedon and Sympazan, managing legal exposure, and pursuing acquisitions.

Financial highlights

• Q4 product sales were $29.6 million, up from $28.7 million in Q3; full-year product sales were $120.8 million.

• Q4 net loss was $10.5 million (GAAP), compared to $2.9 million in Q3; full-year net loss was $21.6 million, improved from $331.9 million in 2023.

• Q4 gross margin was 61%, down from 74% in Q3 due to $2.9 million in Indocin inventory write-downs; excluding charges, gross margin was 71%.

• Q4 adjusted EBITDA was -$0.5 million (vs. $5.3 million in Q3); full-year adjusted EBITDA was $17.1 million, down from $67.7 million in 2023.

• Cash and investments at year-end totaled $100.1 million; debt was $40 million with no maturities until September 2027.

Outlook and guidance

• 2025 net sales guidance is $108–$123 million; adjusted EBITDA guidance is $10–$19 million.

• 2025 focus includes revenue growth in Rolvedon and Sympazan, cost management, and strategic acquisitions.

• Modest Rolvedon growth and double-digit Sympazan growth are expected, offset by continued Indocin decline and flat-to-slightly-declining rest of portfolio.

• Q1 2025 Rolvedon sales expected to be lower than Q4, with Q2 growth anticipated.

• Strategic options, including potential acquisitions, are under evaluation but not included in current guidance.